How does Johnson & Johnson's medical device business differ from Merck's pharmaceutical focus?

Johnson & Johnson operates both pharmaceutical and medical device segments, providing diversification since medical device revenue is tied to elective procedure volumes rather than drug patent cycles, while Merck concentrates almost entirely on pharmaceuticals, particularly its oncology immunotherapy franchise, making its results more dependent on drug pipeline success and patent timelines.

What metrics matter most when comparing JNJ and MRK?

For Johnson & Johnson, watch pharmaceutical pipeline progress across key therapeutic areas and medical device segment growth. For Merck, focus on oncology franchise revenue growth and patent life, along with pipeline progress to diversify beyond its largest current products.

Why is pipeline diversification important for Merck compared to Johnson & Johnson?

Merck's revenue is more concentrated in its leading oncology immunotherapy franchise, so successfully diversifying its pipeline into new therapeutic areas is critical to offsetting eventual revenue pressure once that franchise faces patent expiration, while Johnson & Johnson's more diversified pharmaceutical and medical device business already spreads this concentration risk across multiple product categories.

How is the AI score calculated?

The AI score is a composite signal incorporating fundamental quality, valuation, momentum, analyst sentiment, and risk factors. A higher score indicates a more favorable overall setup relative to the market at the time of the latest update.

Data as of: August 23, 2026

brimindinvest.com / compare / jnj-vs-mrkLIVE

JNJ

Johnson & Johnson · Healthcare

N/A

N/A this month

VERSUS

COMPARE

MRK

Merck & Co., Inc. · Healthcare

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

JNJ N/A

MRK N/A

1Y Returni

JNJ N/A

MRK N/A

Fwd P/Ei

JNJ N/A

MRK N/A

Target Up.i

JNJ N/A

MRK N/A

Op. Margini

JNJ N/A

MRK N/A

Quick take

JNJ vs MRK Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

Johnson & Johnson and Merck are both major global healthcare companies, but Johnson & Johnson diversifies across pharmaceuticals and medical devices, while Merck concentrates more heavily on pharmaceuticals, particularly its leading oncology immunotherapy franchise, alongside a vaccine portfolio.

Johnson & Johnson offers exposure to a diversified healthcare business spanning pharmaceuticals and medical devices with a long dividend growth history, while Merck offers a more concentrated bet on its oncology franchise and pharmaceutical pipeline. Consider whether you prefer Johnson & Johnson's diversification or Merck's oncology-focused growth profile.

Normalized 1Y performance

JNJ

MRK

Not enough data to chart yet.

Recent returns

JNJ

MRK

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

JNJ

Price target data unavailable

N/A

MRK

Price target data unavailable

N/A

Who should consider this stock?

JNJ may suit investors who:

Want diversified exposure to both pharmaceuticals and medical devices
Value a long-standing history as a dividend aristocrat with reliable income growth
Believe diversification across multiple therapeutic areas reduces single-product concentration risk
Prefer a more stable, diversified healthcare business over a concentrated pharmaceutical bet

MRK may suit investors who:

Want concentrated exposure to a leading oncology immunotherapy franchise
Believe strong research and development capabilities can sustain pipeline innovation
Value diversification from an established vaccine portfolio alongside oncology
Are comfortable with revenue concentration risk tied to key product patent life

Performance & AI score

Performance & AI score
Metric	JNJ	MRK
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A
1M returni	N/A	N/A
6M returni	N/A	N/A
1Y returni	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	JNJ	MRK
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Growth, profitability & risk

Growth, profitability & risk
Metric	JNJ	MRK
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

JNJ max drawdowniN/A

MRK max drawdowniN/A

JNJ max wkly dropiN/A

MRK max wkly dropiN/A

5Y risk snapshot

JNJ max drawdowniN/A

MRK max drawdowniN/A

JNJ max wkly dropiN/A

MRK max wkly dropiN/A

10Y risk snapshot

JNJ max drawdowniN/A

MRK max drawdowniN/A

JNJ max wkly dropiN/A

MRK max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	JNJ	MRK
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

JNJ

+2.8%BUY

MRK

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	JNJ	MRK
Company	Johnson & Johnson	Merck & Co., Inc.
Sector	Healthcare	Healthcare
Industry	N/A	N/A
Core business	A diversified global healthcare company operating pharmaceutical and medical device segments, developing treatments across immunology, oncology, and neuroscience while manufacturing a broad range of medical devices used in surgery and other procedures.	A global pharmaceutical company with a significant oncology franchise centered on its immunotherapy portfolio, alongside vaccines and animal health products, focused heavily on research and development of innovative prescription medicines.
Investor focus	Pharmaceutical pipeline progress across key therapeutic areas, medical device segment growth, and dividend growth track record as a long-standing dividend aristocrat.	Oncology franchise revenue growth and patent life, vaccine portfolio performance, and pipeline progress to diversify beyond its largest current products.

JNJ strengths

Diversified business spanning pharmaceuticals and medical devices reduces dependence on any single product category or therapeutic area
Long-standing history as a dividend aristocrat provides a reliable and growing income stream for shareholders
Broad pipeline across immunology, oncology, and neuroscience supports multiple avenues for future growth

MRK strengths

Leading oncology immunotherapy franchise generates substantial revenue and cash flow to fund ongoing research and development
Established vaccine portfolio provides diversification beyond its core oncology business
Strong research and development capabilities support a robust pipeline of potential future therapies across multiple disease areas

Risks to watch — JNJ

Faces ongoing patent expirations across its pharmaceutical portfolio that require pipeline replenishment to offset revenue loss
Medical device segment growth is tied to elective procedure volumes, which can be sensitive to broader healthcare spending trends
Legal and litigation matters have historically created periodic overhangs on investor sentiment

Risks to watch — MRK

Significant revenue concentration in its leading oncology franchise creates exposure to eventual patent expiration
Pipeline diversification efforts must succeed to offset revenue pressure as key products face future competition
Pharmaceutical companies face ongoing regulatory and pricing pressure risk across major markets

Frequently asked questions

JNJ offers diversified exposure to both pharmaceuticals and medical devices with a long dividend growth history, while MRK offers a more concentrated bet on its leading oncology franchise and pharmaceutical pipeline. The better choice depends on whether you prefer diversification or a more concentrated oncology-focused growth profile.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons